Design and in silico modeling of Indoloquinoxaline incorporated keratin nanoparticles for modulation of glucose metabolism in 3T3-L1 adipocytes.
3T3-L1 adipocytes
Indoloquinoxaline
glucose uptake
in silico modeling
keratin nanoparticles
Journal
Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
30
12
2018
revised:
29
08
2019
accepted:
04
09
2019
pubmed:
10
9
2019
medline:
9
6
2021
entrez:
10
9
2019
Statut:
ppublish
Résumé
The following study was done to assess the glucose utilizing efficiency of Indoloquinoxaline derivative incorporated keratin nanoparticles (NPs) in 3T3-L1 adipocytes. Indoloquinoxaline derivative had wide range of biological activities including antidiabetic activity. In this view, Indoloquinoxaline moiety containing N, N-dimethyl (3-fluoro-6H-indolo [3,2-b] quinoxalin-6-yl) methanamine compound was designed and synthesized, and further it is incorporated into keratin nanoparticles. The formulated NPs, drug entrapment efficiency, releasing capacity, stability, and physicochemical properties were characterized by various spectral analyzer and obtained results of characterizations were confirmed the properties of NPs. The analysis of mechanism underlying the glucose utilization of NPs was examined through molecular docking with identified target, and observed in silico study reports shown strong interaction of NPs in the binding pockets of AMPK and PTP1B. Based on the in silico screening, the formulated NPs was performed for in vitro cellular viability and glucose uptake studies on 3T3-L1 adipocytes. Interestingly, 40 μg of NPs displayed 78.2 ± 2.76% cellular viability, and no cell death was observed at lower concentrations. Further, the concentration dependent glucose utilization was observed at different concentrations of NPs in 3T3-L1 adipocytes. The results of NPs (40 μg) on glucose utilization have revealed eminent result 58.56 ± 4.54% compared to that of Metformin (10 μM) and Insulin (10 μM). The identified results clearly indicated that Indoloquinoxaline derivative incorporated keratin NPs significantly increased glucose utilization efficiency and protect the cells against the insulin resistance.
Substances chimiques
Quinoxalines
0
Keratins
68238-35-7
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2904Informations de copyright
© 2019 American Institute of Chemical Engineers.
Références
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068-1083.
Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med. 2013;23(3):266-280.
Rizzo MR, Marfella R, Barbieri M, et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetics. Diabetes Care. 2010;33(10):2169-2174.
Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol. 2013;4:1-12.
Bakke J, Haj FG. Protein-tyrosine phosphatase 1B substrates and metabolic regulation. Semin Cell Dev Biol. 2015;37:58-65.
Schultze SM, Hemmings BA, Niessen M, Tschopp O. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med. 2012;14:1-21.
Das SK, Elbein SC. The genetic basis of type 2 diabetes. Cell. 2006;2(4):100-131.
Fulco M, Sartorelli V. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle. 2008;7(23):3669-3679.
Xue B, Pulinilkunnil T, Murano I, et al. Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues. Mol Cell Biol. 2009;29(16):4563-4573.
Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003;546(1):113-120.
Dadke S, Kusari J, Chernoff J. Down-regulation of insulin signaling by protein-tyrosine phosphatase 1B is mediated by an N-terminal binding region. J Biol Chem. 2000;275(31):23642-23647.
Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007;5(4):237-252.
Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(3):318-326.
Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017;23(7):804-814.
Pandeya SN, Smitha S, Jyoti M, Sridhar SK. Biological activities of isatin and its derivatives. Acta Pharm. 2005;55(1):27-46.
Sharma VM, Seshu KA, Krishna CV, et al. Novel 6, 7-diphenyl-2, 3, 8, 8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agents. Bioorg Med Chem Lett. 2003;13(10):1679-1682.
Moon MJ, Lee SK, Lee J-W, et al. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg Med Chem. 2006;14(1):237-246.
Abadi AH, Abou-Seri SM, Abdel-Rahman DE, Klein C, Lozach O, Meijer L. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. Eur J Med Chem. 2006;41(3):296-305.
Gürsoy A, Karalı N. Synthesis and primary cytotoxicity evaluation of 3-[[(3-phenyl-4 [3H]-quinazolinone-2-yl) mercaptoacetyl] hydrazono]-1H-2-indolinones. Eur J Med Chem. 2003;38(6):633-643.
Nauduri D, Reddy GBS. Antibacetrials and antimycotics: Part 1: synthesis and activity of 2-pyrazoline derivatives. Chem Pharm Bull. 1998;46(8):1254-1260.
Dawane BS, Konda SG, Mandawad GG, Shaikh BM. Poly (ethylene glycol)(PEG-400) as an alternative reaction solvent for the synthesis of some new 1-(4-[4′-chlorophenyl]-2-thiazolyl)-3-aryl-5-(2-butyl-4-chloro-1H-imidazol-5yl)-2-pyrazolines and their in vitro antimicrobial evaluation. Eur J Med Chem. 2010;45(1):387-392.
Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein nanoparticles as drug delivery carriers for cancer therapy. Biomed Res Int. 2014;2014:1-12.
Chowdhury A, Kunjiappan S, Panneerselvam T, Somasundaram B, Bhattacharjee C. Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. Int Nano Lett. 2017;7(2):91-122.
Diab R, Jaafar-Maalej C, Fessi H, Maincent P. Engineered nanoparticulate drug delivery systems: the next frontier for oral administration? AAPS J. 2012;14(4):688-702.
Kunjiappan S, Panneerselvam T, Prasad P, et al. Design, graph theoretical analysis and in silico modeling of Dunaliella bardawil biomass encapsulated keratin nanoparticles: a scaffold for effective glucose utilization. Biomed Mater. 2018;13(4):045012.
Gupta A. Human hair “waste” and its utilization: gaps and possibilities. J Waste Manag. 2014;2014:1-17.
Kunjiappan S, Chowdhury A, Somasundaram B, Bhattacharjee C, Periyasamy S. Optimization, preparation and characterization of rutin-quercetin dual drug loaded keratin nanoparticles for biological applications. Nanomed J. 2016;3(4):253-267.
Kunjiappan S, Panneerselvam T, Somasundaram B, et al. Design, graph theoretical analysis and insilico modeling of Dunaliella bardawil biomass encapsulated N-succinyl chitosan nanoparticles for enhanced anticancer activity. Anticancer Agents Med Chem. 2018;18(13):1900-1918.
Kunjiappan S, Panneerselvam T, Somasundaram B, Arunachalam S, Sankaranarayanan M, Parasuraman P. Preparation of liposomes encapsulated Epirubicin-gold nanoparticles for tumor specific delivery and release. Biomed Phys Eng Exp. 2018;4(4):045027.
Rydberg P, Gloriam DE, Olsen L. The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics. 2010;26(23):2988-2989.
Hashem HM, Mahrouse MA. In vitro metabolism study of a novel P38 kinase inhibitor: in silico predictions, structure elucidation using MS/MS-I. Future Med Chem. 2018;10(02):201-220.
Parasuraman P, Suresh RP. Balancing anti-amyloid and anti-cholinesterase capacity in a single chemical entity: in silico drug design. Int J Pharm Pharm Sci. 2014;6(2):571-574.
Theivendren P, Kunjiappan S, Govindraj S, et al. Graph theoretical analysis, in silico modeling and formulation of pyrimidine nanoparticles as p38α MAP kinases inhibitors: a quantitative proteomics approach. Drug Res. 2018;69(2):100-110.
Jarvill-Taylor KJ, Anderson RA, Graves DJ. A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. J Am Coll Nutr. 2001;20(4):327-336.
Chowdhury A, Kunjiappan S, Bhattacharjee C, Somasundaram B, Panneerselvam T. Biogenic synthesis of Marsilea quadrifolia gold nanoparticles: a study of improved glucose utilization efficiency on 3T3-L1 adipocytes. In Vitro Cell Dev Biol Anim. 2017;53(6):483-493.
Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014;63(7):2253-2261.
Mondal P, Jana S, Balaji A, Ramakrishna R, Kanthal L. Synthesis of some new isoxazoline derivatives of chalconised indoline 2-one as a potential analgesic, antibacterial and anthelmimtic agents. J Young Pharm. 2012;4(1):38-41.
Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm. 2010;7(6):1959-1973.
Chithrani BD, Chan WC. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 2007;7(6):1542-1550.
Chan WC, Maxwell DJ, Gao X, Bailey RE, Han M, Nie S. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol. 2002;13(1):40-46.
Sohaebuddin, S. K.; Thevenot, P. T.; Baker, D.; Eaton, J. W.; Tang, L., Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol 2010, 7, (1), 22, 1-17.
Viollet B, Lantier L, Devin-Leclerc J, et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci. 2009;1(14):3380-3400.
Littler DR, Walker JR, Davis T, et al. A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP-binding site and catalytic loop refolding as a means of regulation. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010;66(2):143-151.
Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 2006;116(7):1776-1783.
Viollet B, Andreelli F. AMP-activated protein kinase and metabolic control. Diabetes-perspectives in drug therapy. Switzerland: Springer; 2011:303-330.
Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci. 2004;29(1):18-24.
Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15-25.
Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol. 2006;574(1):41-53.
Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3(4):267-277.
Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34(2-3):121-138.
Miles P, Higo K, Romeo OM, Lee M-K, Rafaat K, Olefsky JM. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes. 1998;47(3):395-400.
Sandouk T, Reda D, Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology. 1993;133(1):352-359.
Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51(7):2074-2081.
Shao D, Tian R. Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol. 2011;6(1):331-351.
Castro AJG, Frederico MJS, Cazarolli LH, et al. The mechanism of action of ursolic acid as insulin secretagogue and insulinomimetic is mediated by cross-talk between calcium and kinases to regulate glucose balance. Biochim Biophys Acta (BBA). 2015;1850(1):51-61.
Müller G, Wied S. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes. 1993;42(12):1852-1867.
Yonemitsu S, Nishimura H, Shintani M, et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes. 2001;50(5):1093-1101.